BD Diagnostics - Geneohm

Important Notice:
The information provided here is for informational purposes only and does not constitute reimbursement or legal advice. BD makes no warranty or representation regarding the completeness, accuracy, or timeliness of the information provided. CPT coding selection is the sole responsibility of the provider of medical services. Moreover, payers have differing medical and payment policies, and laws, regulations and payer policies concerning reimbursement are complex and change frequently. Accordingly, BD strongly recommends that you consult with your payers, reimbursement specialist(s) and/or legal counsel regarding coding, coverage, and payment matters. BD cannot and does not guarantee or in any way represent that any codes or coding uses will be viewed as acceptable by the AMA, any private payers, any public payers including Medicare, Medicaid, and other governmental-based programs, or any other payer-related organization. BD provides no guarantee as to the reliability of the information contained herein and assumes no liability for any actions taken in reliance thereon. Any action taken in reliance on any document or information provided herein shall be at the actor's own and sole risk. Each provider entity must conduct its own assessment and research to determine the most appropriate codes and coding uses that will be acceptable to the payers with which it deals.

BD GeneOhm™ products assist in Transforming Patient Care™ by delivering rapid nucleic acid based diagnostic solutions. Our current assays for Group B Streptococcus (GBS), methicillin-resistant Staphylococcus aureus (MRSA), and our combination assay for methicillin-resistant Staphylococcus aureus and Staphylococcus aureus (MRSA and SA), have been developed to improve patient outcomes by delivering cost-effective and rapid diagnostic solutions. Visit the BD Diagnostics - GeneOhm website.

• BD GeneOhm™ Assays - Reimbursement Information
• 2013 Clinical Laboratory Fee Schedule